FDA Charges Two Indian Nationals In Fake Ozempic Ring

A federal indictment unsealed September 29 exposes a supply chain integrity failure that QA directors and regulatory leads in the GLP-1 space cannot afford to treat as an isolated criminal matter. The U.S. Department of Justice, supported by FDA's Office of Criminal Investigations, charged Swapnadip Roy, 33, and Vicky Ramancha, 37, both Indian nationals, with conspiracy and smuggling tied to a transnational counterfeit prescription drug distribution scheme targeting the U.S. market.

According to court documents, between July 2023 and April 2024, Roy and Ramancha allegedly sourced counterfeit Ozempic from unauthorized suppliers in China and moved it through a network of co-conspirators into U.S. distribution channels, including pharmacies. The counterfeit product allegedly replicated packaging, package inserts, pen labels, and needles with sufficient fidelity to deceive downstream customers. Deeply discounted pricing was the apparent mechanism used to penetrate legitimate distribution networks.

The timeline carries a specific compliance signal: court documents allege the defendants continued distributing counterfeit product after FDA's December 2023 public safety alert and seizure action. That persistence, operating through and beyond a known enforcement event, points to gaps in downstream distributor due diligence that go beyond this case. For plant heads and QA directors, the question is whether current track-and-trace controls and authorized distributor verification protocols would have flagged anomalous pricing or sourcing patterns before product reached pharmacy shelves.

The GLP-1 category's demand surge has made it a predictable target. Ozempic's supply constraints and high patient demand created the pricing arbitrage that counterfeit networks exploit. Facilities manufacturing or distributing high-demand injectables should treat this indictment as a prompt to audit distributor qualification records, review 21 CFR Part 211 incoming material controls, and confirm that serialization and verification steps under the Drug Supply Chain Security Act are functioning as intended rather than as documented.

FDA Acting Commissioner Kyle Diamantas noted the agency's intent to trace illicit networks across borders and through complex supply chains, signaling that OCI-led investigations into counterfeit distribution are an ongoing enforcement priority, not a reactive response to a single incident.

The indictment is an allegation; Roy and Ramancha are presumed innocent until proven guilty. Entities with knowledge of counterfeit or tampered medicines can report directly to FDA through its online reporting portal.

The next measurable checkpoint for the industry is whether distributor qualification audits and DSCSA verification logs can demonstrate, on inspection, that anomalous sourcing would have been intercepted before product entered the dispensing chain.

Source: FDA Office of Criminal Investigations via FDA.gov press release, September 29, 2026.